Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Stemtech (STEK) Cash & Equivalents (2020 - 2025)

Stemtech's Cash & Equivalents history spans 6 years, with the latest figure at $255416.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 1.6% year-over-year to $255416.0; the TTM value through Sep 2025 reached $255416.0, down 1.6%, while the annual FY2024 figure was $255298.0, 123.62% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $255416.0 at Stemtech, down from $272450.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.6 million in Q3 2021 and bottomed at $114166.0 in Q4 2023.
  • The 5-year median for Cash & Equivalents is $273999.0 (2024), against an average of $384703.2.
  • The largest annual shift saw Cash & Equivalents skyrocketed 1372.4% in 2021 before it plummeted 92.3% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $828206.0 in 2021, then tumbled by 84.0% to $132487.0 in 2022, then fell by 13.83% to $114166.0 in 2023, then surged by 123.62% to $255298.0 in 2024, then grew by 0.05% to $255416.0 in 2025.
  • Per Business Quant, the three most recent readings for STEK's Cash & Equivalents are $255416.0 (Q3 2025), $272450.0 (Q2 2025), and $305836.0 (Q1 2025).